Cyagen and Neurophth collaborate to develop AAV gene therapy vectors for ophthalmic disorders

Nov. 8, 2022

Cyagen Biomodels LLC has established a strategic collaboration with Neurophth Therapeutics Inc. to codevelop next-generation AAV gene therapy vectors for specific types of genetic ophthalmic disorders.

BioWorld Science Collaboration Ocular Gene therapy

Today's news in brief

BioWorld

BioWorld briefs for Nov. 12, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Nov. 12, 2025.

‘Most complete’ map of oral microbiome enables links to systemic disease

BioWorld

South Korean researchers led by Lee In-suk of Yonsei University have reported the most complete oral microbiome catalog to date, with more than 72,000 genomes....

Antibody-drug conjugates floating on light purple background

Sutro Biopharma outlines ADC pipeline

BioWorld Science

Sutro Biopharma Inc. has outlined its next-generation antibody-drug conjugate (ADC) pipeline following recent IND clearance and initiation of phase I for its...

Gentibio’s GNTI-823 promotes renal repair in AKI models

BioWorld Science

Gentibio Inc. has developed and presented data for GNTI-823, an allogeneic tissue Treg engineered from peripheral blood CD4+ T cells with CRISPR-based editing to...